BIO89-100 Demonstrated Robust Reductions in Liver Fat, Improved Metabolic Parameters, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH

Autor: Frias, Juan Pablo, Ortiz-Lasanta, Grisell, Hartsfield, Cynthia L., Tseng, Leo, Charlton, R. William, Mansbach, Hank, Margalit, Maya, Loomba, Rohit
Zdroj: In Metabolism March 2022 128 Supplement
Databáze: ScienceDirect
Externí odkaz: